<div class="p4l_caption"><div class="p4l_captionTitle"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3814639/" ref="ordinalpos=2701&amp;ncbi_uid=6032992&amp;link_uid=PMC3814639" image-link="/pmc/articles/PMC3814639/figure/F3/" class="imagepopup">Figure 3. From: The emerging role of the Nrf2-Keap1 <span class="highlight" style="background-color:">signaling</span> <span class="highlight" style="background-color:">pathway</span> in cancer. </a></div><br /><div class="p4l_captionBody">Cross-talk between Nrf2 and other proteins. The substrate adaptor sequestosome 1 protein (p62) modulates the Nrf2â€“Keap1 signaling pathway by directly interacting with Keap1. p62 sequesters Keap1 in autophagosomes, which results in a decrease in Nrf2 ubiquitination, an increase in Nrf2 stability, and activation of Nrf2 target genes. Nrf2 is stabilized in response to p21 up-regulation. p21 associates with the DLG motif on Nrf2, thereby disrupting the ability of Keap1 to properly bind and ubiquitinate Nrf2. DPP3 binds to Keap1, inhibits Nrf2 ubiquitination, and drives Nrf2-dependent transcription in cancer cells. (E) ETGE; (S) STGE; (D) DLG.</div></div>